GlassScriptPhysician profile
Alde Gavino
NPI 1255534863
$109,911.46
in general payments reported to CMS, 2019-2025
45 companies · $39K in 2025
The $39K reported for 2025 was more than what 98% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
See the full distribution for Dermatopathology (Dermatology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,285 · 2020: $5,883 · 2021: $3,795 · 2022: $8,178 · 2023: $18K · 2024: $30K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $18K · Travel and Lodging: $6,996 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,922.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,396.94 |
| Food and Beverage | $18,244.29 |
| Travel and Lodging | $6,996.18 |
| Education | $210.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $50,380.34 | 2019-2025 | |
| Abbvie INC. | $14,715.23 | 2019-2025 | |
| Incyte Corporation | $13,172.73 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $4,200.02 | 2019-2025 | Tremfya, Stelara, Simponi |
| Ucb, INC. | $3,010.58 | 2019-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $2,882.74 | 2022-2024 | Vtama |
| Leo Pharma INC. | $2,315.83 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $2,263.71 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,793.01 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Genzyme Corporation | $1,710.16 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,593.39 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $1,407.61 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Almirall LLC | $1,262.53 | 2019-2022 | |
| Medimetriks Pharmaceuticals, INC. | $1,176.16 | 2019-2023 | Clindacin Etz |
| Amgen INC. | $1,006.84 | 2020-2025 | Otezla, Otezla |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $941.40 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Merz North America, INC. | $757.09 | 2020-2024 | Xeomin |
| Mayne Pharma Commercial LLC | $734.13 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $681.93 | 2019-2023 | Arazlo |
| Arcutis Biotherapeutics, INC. | $654.18 | 2023-2025 | Zoryve |
| Kerecis Limited | $461.39 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| E.R. Squibb & Sons, L.L.C. | $390.45 | 2023-2025 | Sotyktu |
| Encore Dermatology INC. | $372.52 | 2019-2020 | |
| Regeneron Pharmaceuticals, INC. | $252.90 | 2023-2025 | Dupixent |
| Organon LLC | $224.85 | 2025 | Vtama |
| Biofrontera INC. | $188.80 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Genentech USA, INC. | $179.28 | 2019-2021 | |
| Journey Medical Corporation | $152.46 | 2019-2023 | |
| Vyne Pharmaceuticals INC. | $130.14 | 2020-2021 | |
| Epi Health, LLC | $118.71 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Mimedx Group, INC. | $86.39 | 2024-2025 | |
| Revance Therapeutics, INC. | $80.29 | 2024-2025 | Daxi, Daxxify |
| Mission Pharmacal Company | $74.98 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $61.26 | 2020-2024 | Nuzyra |
| Strata Skin Sciences, INC. | $60.94 | 2022-2023 | Xtrac |
| Celgene Corporation | $57.95 | 2019 | |
| Verrica Pharmaceuticals INC. | $47.45 | 2024 | Ycanth |
| Allergan, INC. | $47.32 | 2019-2021 | |
| Elekta, INC. | $41.54 | 2024 | Elekta Medical Linear Accelerator |
| Glenmark Therapeutics INC. | $40.00 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $30.20 | 2019 | |
| Lumenis, INC | $24.00 | 2021 | |
| Taro Pharmaceuticals USA, INC. | $14.41 | 2019 | |
| Dermira, INC. | $13.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alde Gavino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.